Cerenome Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Los beneficios de Cerenome han disminuido a una tasa media anual de -7%, mientras que en la industria Biotechs los beneficios crecieron en un 33.4% anualmente. Los ingresos han ido creciendo a una tasa media de 44.8% al año.
Información clave
-7.02%
Tasa de crecimiento de los beneficios
57.40%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 17.04% |
| Tasa de crecimiento de los ingresos | 44.82% |
| Rentabilidad financiera | -477.54% |
| Margen neto | -620.70% |
| Última actualización de beneficios | 30 Jun 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
Actualización de narrativa • Sep 11
CNSY: CNS Delivery Platform And CSF Assay Expansion Will Drive Future Upside
Analysts have reset their price target for Cerenome from $38.00 to $32.50, reflecting updated assumptions on higher projected revenue growth, wider profit margins, a slightly higher discount rate, and a lower future P/E multiple. What’s in the News for Cerenome Cerenome plans a private placement of senior secured convertible notes with 3i, LP with an aggregate original principal amount of US$21,276,596 at a 6% original issue discount, for expected proceeds of about US$20,000,000.24.
Actualización de narrativa • Jul 06
PSTV: CNSide Coverage And Rebranding Will Reprice Future CNS Oncology Shares
Analysts have trimmed their 12 month price target on Plus Therapeutics to $57 from $65, citing updated fair value assumptions, a modestly higher discount rate, and revised estimates for future revenue growth, profit margins, and P/E multiples. What’s in the News for Plus Therapeutics Plus Therapeutics announced a corporate rebranding to Cerenome, with its Nasdaq ticker expected to change from PSTV to CNSY effective August 3, 2026, according to its mid year business update.
Actualización de narrativa • Jun 22
PSTV: CNS Oncology Pipeline And New CPT Code Will Drive Upside
Analysts have adjusted their fair value estimate for Plus Therapeutics stock from $1 to $12, citing updated assumptions around discount rates, revenue growth, profit margins and a lower future P/E multiple as key drivers of the new price target framework. Analyst Commentary Recent Street research on Plus Therapeutics signals a more cautious tone, with bearish analysts revisiting their assumptions around valuation, execution risk and the pace at which the company may be able to translate its pipeline into financial results.Actualización de narrativa • Jun 08
PSTV: Future CNS Oncology CPT Codes Will Reprice Shares Despite Downgrades
Analysts have reduced their price target on Plus Therapeutics by $25.50, reflecting updated views on the company’s growth prospects and risk profile following recent research revisions from the Street. Analyst Commentary Recent Street research on Plus Therapeutics highlights a mix of caution and potential upside, with price targets and ratings being recalibrated to reflect updated views on execution risk and commercialization timelines.Actualización de narrativa • May 24
PSTV: Future Brain Cancer CPT Codes Could Reprice Shares Despite Recent Downgrades
Analysts have cut their price target on Plus Therapeutics by $25.50, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples following recent downgrades and target revisions. Analyst Commentary Recent research notes highlight a shift in how analysts frame the risk and reward around Plus Therapeutics.Actualización de narrativa • May 02
PSTV: CNS Delivery And New CPT Codes Will Drive Future Upside
Analysts have adjusted their view on Plus Therapeutics, cutting the average price target by $25.50 while updating their models for fair value, discount rate, profit margin and future P/E to reflect a mix of rating changes and new coverage. Analyst Commentary Recent Street research on Plus Therapeutics reflects a mix of optimism about long term potential and caution around execution and valuation, with one firm initiating coverage positively and others resetting expectations through a downgrade and a lower price target.Actualización de narrativa • Apr 18
PSTV: Future Brain Cancer CPT Codes And Delivery Technique Could Reprice Shares
Narrative Update The updated analyst price target for Plus Therapeutics moves from about $475 to roughly $65, as analysts cite recent target cuts and a downgrade, along with one newer bullish initiation that together lead to a more tempered but still constructive set of assumptions on revenue growth, margins, and future P/E. Analyst Commentary Recent Street research on Plus Therapeutics shows a mix of caution and optimism, with several firms trimming targets and one newer, more constructive initiation helping to reset expectations rather than support extreme outcomes.Actualización de narrativa • Apr 03
PSTV: Future Brain Cancer CPT Code And FDA Dialogue Could Reprice Shares
The analyst price target for Plus Therapeutics has shifted from $20.50 to $475.00, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E. This change is informed by recent mixed Street research that includes a downgrade from D.Actualización de narrativa • Mar 20
PSTV: Upcoming CNS Milestones And New CPT Code Will Shape Upside Potential
Narrative Update on Plus Therapeutics Analysts have trimmed their price targets on Plus Therapeutics by about $1 to $1.50, reflecting revised views on profit margin potential and valuation, while still citing supportive research coverage for the story. Analyst Commentary Recent research updates paint a mixed picture for Plus Therapeutics, with one initiation taking a constructive stance and other reports trimming price targets by $1 to $1.50.Actualización de narrativa • Mar 06
PSTV: FDA Pivotal Trial Design And Brain Cancer Pipeline Will Drive Upside
Analysts have reduced their blended price target on Plus Therapeutics by about $0.60, reflecting updated views on fair value, revenue growth expectations, profit margins, and future P/E following recent initiations and target changes from several firms. Analyst Commentary Recent Street research on Plus Therapeutics shows a mix of views, with some firms starting coverage positively while others are taking a more conservative stance through reduced price targets.Actualización de narrativa • Feb 19
PSTV: Upcoming CNS Milestones And Diagnostics Rollout Will Drive Future Upside
Analysts have trimmed their average Plus Therapeutics price target by $2.50, citing updated assumptions around discount rates, profit margins and a higher future P/E multiple, while still maintaining their fair value estimate at $5.50. Analyst Commentary Bullish Takeaways Bullish analysts point to enough upside against the current trading price to justify a fresh positive view, even after trimming inputs such as discount rates and profit margins.Actualización de narrativa • Feb 05
PSTV: Upcoming CNS Trials And Diagnostics Expansion Will Drive Upside Potential
Analysts have revised their price targets for Plus Therapeutics lower, with the implied fair value estimate moving from about $9.67 to $5.50 as they incorporate updated assumptions for revenue growth, profit margins, discount rates, and a lower future P/E multiple following recent research updates. Analyst Commentary Recent research updates offer a mixed picture of how analysts are thinking about Plus Therapeutics, with some seeing attractive upside potential and others tempering expectations through lower price targets.Actualización de narrativa • Jan 22
PSTV: FDA Pivotal Trial Progress Will Drive Future Upside Potential
Narrative Update on Plus Therapeutics Analysts have adjusted their price target for Plus Therapeutics to US$1.63. The change is linked to updated assumptions for discount rate, revenue growth, profit margin, and a revised forward P/E of 49.25x, which reflect their refreshed outlook on the company’s risk and earnings potential.Actualización de narrativa • Jan 06
PSTV: Advancing Central Nervous System Cancer Trials And Grant Funding Will Drive Upside Potential
Analysts have raised their price target on Plus Therapeutics to US$1.63 per share, reflecting updated assumptions that now pair a revenue growth estimate of 96.95% with a slightly higher discount rate of 7.18%, a lower future P/E of 51.69x, and a modestly adjusted profit margin outlook of 16.24%. What's in the News Presented three clinical data updates at the WFNOS/SNO Annual Meeting in Honolulu covering multiple doses of Rhenium (186Re) Obisbemeda (Reyobiq) for leptomeningeal metastases, including rationale, design, and preliminary Cohort 1 data (Key Developments).Actualización de narrativa • Dec 15
PSTV: Expanded Brain Cancer Pipeline And Funding Will Drive Upside Potential
Narrative Update on Plus Therapeutics Analysts have raised their price target on Plus Therapeutics to approximately 83.96 from about 114.72, citing a modestly higher assumed discount rate, slightly lower long term profit margins, and somewhat stronger revenue growth expectations that together point to a more balanced, though still optimistic, valuation profile. What's in the News Presented three positive clinical data updates at the WFNOS/SNO Annual Meeting, including early ReSPECT-LM multidose trial results showing REYOBIQ was well tolerated at initial dosing levels and supporting continued dose optimization for leptomeningeal metastases patients (company announcement).Actualización de narrativa • Nov 04
PSTV: 15 Million Financing And Prefunded Warrants Will Drive Clinical Progress
Analysts have raised their fair value estimate for Plus Therapeutics from $7.88 to $9.67, citing updated revenue forecasts and improved capital structure following recent changes in financing. Analyst Commentary Analyst updates on Plus Therapeutics reflect a balanced perspective on the company’s outlook and recent financing changes.Actualización de narrativa • Sep 04
15 Million Financing And Oncology Trials Will Secure Clinical Progress
Analysts lowered their price target for Plus Therapeutics from $8.83 to $7.88 primarily due to anticipated equity dilution from recent financing, which increased outstanding shares and warrants, though they remain positive on the company’s long-term outlook. Analyst Commentary Price target reductions reflect anticipated equity dilution following recent financing activities.Artículo de análisis • Aug 15
We Think Plus Therapeutics (NASDAQ:PSTV) Needs To Drive Business Growth Carefully
NasdaqCM:PSTV 1 Year Share Price vs Fair Value Explore Plus Therapeutics's Fair Values from the Community and select...
Nueva narrativa • Apr 20
15 Million Financing And Oncology Trials Will Secure Clinical Progress
Strengthened financial position and leadership could drive clinical advancements, potentially boosting future revenue and improving earnings growth.Desglose de ingresos y gastos
Desglose de ingresos y gastos
Cómo gana y gasta dinero Cerenome. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 26 | 4 | -26 | 18 | 0 |
| 31 Mar 26 | 5 | -12 | 15 | 0 |
| 31 Dec 25 | 5 | -22 | 12 | 0 |
| 30 Sep 25 | 5 | -21 | 11 | 0 |
| 30 Jun 25 | 5 | -19 | 10 | 0 |
| 31 Mar 25 | 5 | -23 | 11 | 0 |
| 31 Dec 24 | 6 | -13 | 10 | 0 |
| 30 Sep 24 | 6 | -13 | 9 | 0 |
| 30 Jun 24 | 6 | -13 | 9 | 0 |
| 31 Mar 24 | 6 | -12 | 9 | 0 |
| 31 Dec 23 | 5 | -13 | 9 | 0 |
| 30 Sep 23 | 4 | -15 | 10 | 0 |
| 30 Jun 23 | 3 | -17 | 10 | 0 |
| 31 Mar 23 | 1 | -21 | 10 | 0 |
| 31 Dec 22 | 0 | -20 | 10 | 0 |
| 30 Sep 22 | 0 | -19 | 9 | 0 |
| 30 Jun 22 | 0 | -17 | 8 | 0 |
| 31 Mar 22 | 0 | -15 | 8 | 0 |
| 31 Dec 21 | 0 | -13 | 7 | 0 |
| 30 Sep 21 | 0 | -13 | 7 | 0 |
| 30 Jun 21 | 0 | -11 | 6 | 0 |
| 31 Mar 21 | 0 | -10 | 6 | 0 |
| 31 Dec 20 | 0 | -8 | 6 | 0 |
| 30 Sep 20 | 1 | -4 | 6 | 0 |
| 30 Jun 20 | 6 | -2 | 6 | 0 |
| 31 Mar 20 | 6 | -2 | 5 | 0 |
| 31 Dec 19 | 7 | -4 | 5 | 0 |
| 30 Sep 19 | 7 | -7 | 5 | 0 |
| 30 Jun 19 | 2 | -11 | 5 | 0 |
| 31 Mar 19 | 2 | -9 | 5 | 0 |
| 31 Dec 18 | 3 | -11 | 6 | 0 |
| 30 Sep 18 | 4 | -18 | 7 | 0 |
| 30 Jun 18 | 5 | -19 | 8 | 0 |
| 31 Mar 18 | 6 | -24 | 10 | 0 |
| 31 Dec 17 | 6 | -27 | 11 | 0 |
| 30 Sep 17 | 8 | -23 | 11 | 0 |
| 30 Jun 17 | 9 | -24 | 12 | 0 |
| 31 Mar 17 | 10 | -24 | 12 | 0 |
| 31 Dec 16 | 11 | -22 | 12 | 0 |
| 30 Sep 16 | 12 | -20 | 12 | 0 |
| 30 Jun 16 | 12 | -13 | 12 | 0 |
| 31 Mar 16 | 12 | -2 | 12 | 0 |
| 31 Dec 15 | 12 | -19 | 12 | 0 |
| 30 Sep 15 | 12 | -24 | 14 | 0 |
Ingresos de calidad: CNSY actualmente no es rentable.
Margen de beneficios creciente: CNSY actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: CNSY no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 7% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de CNSY en el último año con su promedio de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: CNSY no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (64.6%).
Rentabilidad financiera
Alta ROE: CNSY tiene una rentabilidad financiera negativa (-477.54%), ya que actualmente no es rentable.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/21 18:26 |
| Precio de las acciones al final del día | 2026/09/18 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Cerenome, Inc. está cubierta por 11 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Andrew D'Silva | B. Riley Securities, Inc. |
| John Savin | Edison Investment Research |